SSY GROUP (02005) has obtained the drug production registration certificate for Vitamin K1 injection (1ml: 10mg).
Shijifeng Pharmaceutical Group (02005) announced that the group has obtained the drug production registration approval from the National Medical Products Administration of China for Vitamin K1 injection (1ml:10mg), classified as a Category 3 chemical drug, which is considered equivalent to passing the consistency evaluation.
SSY GROUP (02005) announced that the group has obtained the drug production registration approval from the National Medical Products Administration of China for Vitamin K1 Injection (1ml:10mg), which is classified as a Class 3 chemical drug and is deemed to have passed the consistency evaluation.
Vitamin K1 Injection is mainly used to treat vitamin K deficiency bleeding and to prevent vitamin K deficiency that cannot be addressed through nutritional supplementation. Vitamin K1 Injection is a fundamental clinical medication, widely used for bleeding prevention and emergency treatment, with a large market scale. The approval of this product enriches the group's portfolio of injectable products.
Related Articles
CSPC PHARMA (01093) released its interim results, with net profit attributable to shareholders reported at 6.094 billion yuan, a year-on-year increase of 139.2%.
VSTECS (00856) announced its interim results, with a profit attributable to shareholders of HK$915 million, an increase of 49.87% year-on-year.
WIN HANVERKY (03322) released its interim results, with a profit attributable to equity holders of HK$5.934 million, turning a profit compared to the same period last year.
CSPC PHARMA (01093) released its interim results, with net profit attributable to shareholders reported at 6.094 billion yuan, a year-on-year increase of 139.2%.
VSTECS (00856) announced its interim results, with a profit attributable to shareholders of HK$915 million, an increase of 49.87% year-on-year.
WIN HANVERKY (03322) released its interim results, with a profit attributable to equity holders of HK$5.934 million, turning a profit compared to the same period last year.
RECOMMEND
